Amerikanische Gesellschaft für Hirudotherapie

Off-pump coronary artery bypass with heparin in a patient with a history of heparin-induced thrombocytopenia: a case report

Case report published in Surgical Case Reports (2021)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienSicherheit & InfektionskontrolleIto Y et al. · Surgical Case Reports, 2021

Abstract

BACKGROUND: Cardiovascular surgery for patients with a history of heparin-induced thrombocytopenia (HIT) with thrombosis requires careful perioperative anticoagulation therapy. When cardiovascular surgery is required for patients having 'remote' HIT, such as those who had a history of HIT and platelet factor-4/heparin antibodies turned out to be negative, it is recommended that re-exposure to heparin should be limited only to the intraoperative phase. However, few case reports have described detailed strategies for perioperative anticoagulation regimens. CASE PRESENTATION: We present the case of a 76-year-old woman, presenting with unstable angina pectoris and requiring coronary artery bypass grafting. She had a history of cardiac resuscitation and percutaneous coronary intervention for unstable angina pectoris with ventricular tachycardia 7 years prior, which caused HIT with thrombosis resulting in amputation of four fingers. On admission, platelet factor-4/heparin antibodies, biomarkers for HIT were not detected; the platelet count was 18.0 × 104/µl. Off-pump coronary artery bypass grafting was performed using heparin; argatroban infusion was continued until 9 h prior to the operation and restarted 3 h postoperatively, bridged with regular warfarin from 4 days to 3 months postoperatively. Platelet factor-4 /heparin antibodies were detected on postoperative day 8 without any clinical symptoms and became negative by day 91. CONCLUSION: We consider this anticoagulation strategy is effective especially in countries, where bivalirudin is not available. Re-exposure to heparin in cardiovascular surgery for patients with a history of 'remote HIT' is reasonable, and appropriate anticoagulation is important for an uneventful postoperative course.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

Case report of off-pump CABG in a 76-year-old patient with remote HIT history (post-amputation of four fingers) using brief intraoperative heparin re-exposure bridged with argatroban, where bivalirudin was unavailable.

Warum dies für die Hirudotherapie relevant ist

This case report describes off-pump coronary artery bypass grafting performed with intraoperative heparin in a 76-year-old woman with a history of 'remote' heparin-induced thrombocytopenia, using argatroban before and after surgery and bridging with warfarin postoperatively. Platelet factor-4/heparin antibodies transiently reappeared on postoperative day 8 without clinical symptoms and became negative by day 91. The abstract does not mention lepirudin, hirudin, leech therapy, or any leech-derived anticoagulant. For ASH, this article has no direct relevance to hirudotherapy or the leech secretome; it addresses perioperative anticoagulation strategy using argatroban and warfarin in a single patient with prior HIT.

Zitation

Off-pump coronary artery bypass with heparin in a patient with a history of heparin-induced thrombocytopenia: a case report.

Ito Y et al. · Surgical Case Reports, 2021

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.